Pharmaceutical composition for controlling distant metastasis comprising lactobacillus sakei CVL-001 as active ingredient
The Lactobacillus sakei CVL-001 strain addresses the limitations of current metastatic cancer treatments by inhibiting metastasis through immune regulation, offering a safe and effective solution for controlling distant cancer spread.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- IND FOUND OF CHONNAM NAT UNIV
- Filing Date
- 2025-12-04
- Publication Date
- 2026-07-23
AI Technical Summary
Current treatments for metastatic cancer, such as chemotherapy and immunotherapy, have significant side effects and limitations, and there is a need for a safer, more effective method to inhibit and prevent cancer metastasis.
A pharmaceutical and food composition utilizing the Lactobacillus sakei CVL-001 strain as an active ingredient, which has been shown to inhibit metastasis in animal models by regulating the immune system and reducing lung metastasis.
The Lactobacillus sakei CVL-001 strain effectively reduces the number and area of lung metastases in mouse models, providing a safe and effective means to control, inhibit, or treat distant cancer metastasis with minimal side effects.
Smart Images

Figure KR2025020719_23072026_PF_FP_ABST